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Pathophysiology of Fibrosis
Normal lung healing takes place 
in phases, following the initial injury 
is a period of healing that begins 
during the acute inflammation and 
can take some time to complete.  
Depending on the injury and how 
much damage is present, the tissue 
can regenerate with complete return 
to normal function.  If the damage 
was more severe, resolution is an 
acceptable outcome, this is a return 
to almost normal. During repair, 
scar tissue replaces destroyed tissue.  
This type of healing happens with 
extensive damage and results in 
tissue that is much less viable than it 
was before the injury.  This 
replacement of lung tissue with less 
viable tissue causes lung stiffness 
and ventilation difficulty.  This, in 
turn, results in decreased gas 
exchange and hypoxemia.
• Pulmonary fibrosis is a lung 
disorder characterized by 
development of a fibrotic 
pathway following injury and 
inflammation.
• Initial injury can be caused by 
environmental, biologic, or 
chemical irritants.  Many times 
the cause is unknown.
• Lung fibrosis leads to difficult 
ventilation and perfusion and 
subsequent hypoxemia.
• Current research shows an 
increase in inflammatory 
mediators which stimulate ECM 
deposition. 
• Much research is incomplete or 
conflicting; this indicates a need 
for further investigation.
• Knowledge of pathophysiology 
and current research is crucial 
for healthcare providers in order 
to guide their treatment.
The purpose of this poster is to 
discuss the pathophysiology of 
pulmonary fibrosis.  More 
specifically, the roles of the 
inflammatory and immune 
agents thought to be 
responsible for stimulating 
fibrosis in the lungs will be 
discussed. Pulmonary fibrosis 
(PF) is a chronic disease of the 
lungs involving an altered 
inflammatory response to injury 
or infection which results in 
scarring of lung tissue.  The 
lungs are then unable to 
ventilate or oxygenate 
effectively due to the scar tissue.  
PF has not been thoroughly 
studied compared with many of 
the more prevalent diseases 
today.  PF affects men more 
often than women but has seen 
an increase in both genders 
since 2000.  According to Ley 
and Collard (2013) the lack of 
research in PF is partly due to 
the existence of similar 
comorbidities such as COPD, 
other interstitial lung diseases, 
viral infections, etc.  and the 
unclear definition of PF in the 
past.  
According to Wilson & Wynn (2009) PFers lack MMP-2 and MMP-9, peptidases 
which are required for successful clearance of inflammatory cells. MMP’s help 
determine the amount of collagen deposited during healing.  Some research has 
suggested that the timing of inflammation may be very important in the causation 
of lung fibrosis as well.  On one hand, research has suggested that inflammation 
may not be a factor in PF as anti-inflammatory agents show no improvement. 
What’s more, late-stage inflammation may actually improve the risk of scarring by 
clearing cell debris and controlling excessive proliferation. This evidence just goes 
to show how little is known about PF. (Wilson & Wynn, 2009)  On the other hand, 
more evidence shows that fibrosis is initiated by the inflammatory response at first 
but requires activation of specific pathways to continue collagen production and 
contribution to the extracellular matrix, (Wynn & Ramalingam, 2012).  This view is 
more widely accepted due to the fact that inflammatory mediators are found in 
higher concentrations in PF patients; also, a known risk factor of PF is chronic 
infections which stimulate inflammation.
Not only do PF patients have excessive inflammatory responses but certain cells in 
PF patients have actually shown a heightened sensitivity to some very potent pro 
fibrotic cytokines such as IL-13 and TGFbeta1.  According to a study on the 
responsiveness of fibroblasts, these pro-fibrotic cytokines were shown to interact 
with each other to stimulate a fibrotic response more so than one stimulator by 
itself, (Murray,  Argentieri, Farrell, Bracht, Sheng, Whitaker, Beck, Tsui, Cochlin, 
Evanoff, Hogaboam, & Das, 2008)
Conclusion
References
Differing research findings suggest that there is still much more to be discovered 
of the pathophysiology of PF.  Current understanding of the pathophysiology is 
important for healthcare providers to know in order to determine diagnostic criteria.  
Early and accurate diagnosis greatly influences implementation of an effective 
treatment plan.  Knowing the specific pathophysiology is especially important when 
determining the treatment plan for patients with PF.  Healthcare providers must 
know specifics in disease stages, inflammatory mediator presence, and what these 
mediators indicate regarding the unique sequence of that patient’s condition. 
Knowing the pathophysiology aids critical thinking and clarifies understanding of 
when and why therapies and medications work.
Significance of Pathophysiology
• Nurses must know the 
pathophysiology in order to 
educate PF patients regarding 
their treatments, 
medications, and changes in 
lifestyle.  
• A more thorough 
understanding of the possible 
contributing factors can allow 
the bedside nurse to act as an 
extra filter when checking for 
treatment and medication 
contraindications.  
• There is evidence that certain 
biologic agents that are used 
as treatments and therapies 
can contribute to PF. One 
example exists with a study 
of anti-tumor necrosis factor 
given as a treatment for 
rheumatoid arthritis. Of the 
cases studied, 16% of 
patients developed lung 
fibrosis, (Perez-Alvarez, 
Perez-de-Lis, Diaz-Lagares, 
Pego-Reigosa, Retamozo, & 
Bove, 2014).
• Nurses must know the 
efficacy of the treatments 
they are administering for PF 
patients.
• Nurse Practitioners (NP’s), 
specifically, must know 
diagnostic criteria and 
variables in disease 
presentation. 
• Healthcare providers must 
keep up on new research. 
For example, molecular 
biomarkers show some 
promise in evaluating a 
patient based on their stage 
of PF and their specific 
responses and activated 
pathways regarding 
inflammation and fibrosis.  
This research, however, is 
underpowered and is lacking 
in validation at this time, 
(Hambly, Shimbori, & Kolb, 
2015).   
• It is important for NP’s, as 
leaders in healthcare, to be 
aware of current research to 
aid in accurate diagnoses 
and development the most 
effective treatment plans.
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According to current research, it is clear that there is not just one factor that 
determines the likelihood of developing an altered healing pathway leading to 
fibrosis of the lung.  Altered responses during the reconstructive phase of healing 
lead to increased recruitment of inflammatory and fibrotic mediators such as 
cytokines, chemokines, and growth factors.  Much of the literature confirms that 
these mediators are increased in patients with pulmonary fibrosis (PF). 
Following injury, lung epithelial cells are turned on to signal TGFbeta1 induced 
expression of connective tissue growth factor (CTGF).  CTGF is a pro-fibrotic 
cytokine that is indicated in fibroblast activation which “express/contribute to the 
fibrotic matrix proteins and induce further expression of pro-fibrotic cytokines, 
resulting in progressive fibrosis and establishment of ECM (extra-cellular matrix).” 
(Wilson & Wynn, 2009). Chronic inflammation exposes one to develop fibrosis and 
to turn on pro-fibrotic mediators more readily. The proliferation and recruitment of 
platelets, degranulation, clots, and leukocytes along with the ECM, contribute to the 
blocking of the damaged endothelium from resolution.  
The signs and symptoms of PF are 
due to the over production of 
inflammatory mediators and 
proliferation of scar tissue.  These 
signs and symptoms include, 
shortness of breath, dry cough, 
fatigue, fever, chest pain, weight 
loss, and aching in muscles and 
joints (Wilson & Wynn, 2009).  
Causes of PF
The injurious agents leading to the 
chronic inflammation that precedes 
PF may be an environmental, 
chemical, or biologic irritant.  
Sometimes the cause is unknown such 
as in idiopathic pulmonary fibrosis 
(IPF). IPF is the most common type of 
PF.   
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